2025-12-22 - Analysis Report
Okay, here's a comprehensive report on Albemarle Corp (ALB) based on the provided data.

**1) Return Comparison and Divergence:**

*   **Ticker:** ALB
*   **Company Name:** Albemarle Corp
*   **Overview:** Albemarle Corp is a specialty chemicals company and a leading global producer of lithium, bromine specialties, and catalysts.
*   **ALB Cumulative Return:** 40.97%
*   **S&P 500 (VOO) Cumulative Return:** 100.88%
*   **Divergence:** -59.9 (Relative Divergence: 19.5)

**Analysis:** Albemarle's cumulative return significantly underperformed the S&P 500. The divergence of -59.9 indicates a substantial difference in performance. The relative divergence of 19.5 suggests that the current divergence is near the lower end of its historical range, indicating a possible opportunity or continued underperformance.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha  | Beta  | Cap(B) |
|------------|--------|-------|--------|-------|--------|
| 2015-2017  | 85.0%  | 68.0% | 56.0%  | 0.1   | 15.1   |
| 2016-2018  | 9.0%   | 68.0% | -6.0%  | 0.0   | 9.1    |
| 2017-2019  | -44.0% | 73.9% | -66.0% | 0.1   | 8.6    |
| 2018-2020  | 44.0%  | 79.4% | 20.0%  | 0.2   | 17.4   |
| 2019-2021  | 149.0% | 79.4% | 103.0% | -0.1  | 27.5   |
| 2020-2022  | 148.0% | 79.9% | 149.0% | 0.5   | 25.5   |
| 2021-2023  | -26.0% | 81.9% | -27.0% | 0.5   | 17.0   |
| 2022-2024  | -152.0%| 81.9% | -172.0%| 0.3   | 10.1   |
| 2023-2025  | -180.0%| 81.9% | -246.0%| -0.9  | 17.2   |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate (CAGR) fluctuates significantly, showing periods of high growth (e.g., 2019-2021, 2020-2022) and sharp declines (e.g., 2022-2024, 2023-2025). The recent negative CAGR indicates recent struggles.
*   **MDD:** The Maximum Drawdown (MDD) is consistently high, reflecting significant volatility and risk.  The MDD consistently staying around 80% indicates the stock has lost 80% of its value at its lowest point in each period.
*   **Alpha:** Alpha measures the excess return compared to the market.  The consistently negative Alpha in recent periods (2021-2025) means Albemarle is underperforming relative to the market.
*   **Beta:** Beta measures the stock's volatility relative to the market. The beta is below 1 in most periods, but is negative in one period, suggesting below-market volatility.

**2) Recent Stock Price Fluctuations:**

*   **Close:** 145.88
*   **Last-market:** {'price': 145.88, 'previousClose': 140.48, 'change': 3.84}
*   **5-day SMA:** 136.87
*   **20-day SMA:** 129.06
*   **60-day SMA:** 108.23

**Analysis:** The stock price is currently above all three moving averages, indicating a short-term upward trend. The 5-day SMA is above the 20-day SMA, and the 20-day SMA is above the 60-day SMA, further confirming this trend.  The recent price increase of 3.84 indicates a strong upward movement.

**3) RSI, PPO and Hybrid Signal Analysis:**

*   **Market Risk Indicator (MRI):** 0.7 (Medium Investment)
*   **RSI:** 67.31
*   **PPO:** 0.21
*   **Hybrid Signal:** Cash 0% Buy 80% of cash (3 shares - Caution - MRI:0.70) (Cash Ratio: 0% on 2025-12-19)
*   **Recent (20 days) relative divergence change:** 4.0 (+): Short-term increase
*   **Expected Return (%):** 58.4%

**Analysis:**

*   **MRI:** A medium investment recommendation suggests a moderate level of risk and potential reward.
*   **RSI:** An RSI of 67.31 indicates that the stock is approaching overbought territory (typically above 70), but is not there yet.
*   **PPO:** A slightly positive PPO indicates a potential upward momentum.
*   **Hybrid Signal:** The hybrid signal recommends buying a portion of your cash position (80% or 3 shares) while exercising caution. This is also in agreement with the MRI suggesting a medium investment.
*   **Relative Divergence Change:** The recent increase in relative divergence supports the short-term upward trend.
*   **Expected Return:** A high expected return suggests a positive long-term outlook.

**4) Recent News & Significant Events:**

*   **Positive News:**
    *   **Lithium Price Spike:** Albemarle stock jumped as lithium prices spiked and analysts raised targets.
    *   **Lithium Deficit:** UBS suggests a lithium deficit could boost Albemarle stock.
    *   **Analyst Target Increase:** Analyst has given a $150 price target.
    *   **Lithium and AI:** Albemarle leads the S&P 500 as lithium becomes linked to AI plays.

*   **Neutral/Mixed News:**
    *   **Specialty Chemicals:** Albemarle shares show little change in the specialty chemicals sector.
    *   **Equal-Weight Recommendation:** Wells Fargo maintains an "Equal-Weight" recommendation.

**Analysis:** The recent news is predominantly positive, driven by rising lithium prices and increased analyst optimism. The association of lithium with the growing AI sector is also a bullish sign. However, the "Equal-Weight" recommendation suggests some analysts remain neutral.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy (Mean: 2.42)
*   **Opinions:** 23
*   **Target Price (avg/high/low):** 124.84 / 200.00 / 75.00

**Analysis:** The analyst consensus is a "Buy" rating. The average target price of $124.84 is below the current price of $145.88, suggesting the stock may be overvalued according to these analysts. However, the high target price of $200.00 indicates some analysts see significant upside potential.

**5) Recent Earnings Analysis:**

| 날짜       | EPS     | 매출       |
|------------|---------|------------|
| 2025-11-05 | -1.72   | 1.31 B$    |
| 2025-08-04 | -0.16   | 1.33 B$    |
| 2025-04-30 | 0       | 1.08 B$    |
| 2024-11-06 | -9.45   | 1.35 B$    |
| 2025-11-05 | -9.45   | 1.35 B$    |

**Analysis:** The recent earnings reports show mixed results. While revenue has generally been strong (above $1B), the Earnings Per Share (EPS) have been negative in most of the recent quarters. This suggests that while the company is generating substantial revenue, profitability is a concern.

**6) Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-09-30   | $1.31B     | 8.99%         |
| 2025-06-30   | $1.33B     | 14.80%        |
| 2025-03-31   | $1.08B     | 14.51%        |
| 2024-12-31   | $1.23B     | 11.22%        |
| 2024-09-30   | $1.35B     | -7.68%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE       |
|--------------|------------|-----------|
| 2025-09-30   | $10.00B    | -1.61%    |
| 2025-06-30   | $10.24B    | 0.22%     |
| 2025-03-31   | $10.03B    | 0.41%     |
| 2024-12-31   | $9.96B     | 0.76%     |
| 2024-09-30   | $10.24B    | -10.44%   |

**Analysis:** Revenue has generally been strong, but profitability is inconsistent. The profit margins fluctuate, with one quarter showing a negative margin. The Return on Equity (ROE) is also inconsistent and even negative in some quarters, indicating inconsistent profitability relative to equity.

**7) Comprehensive Analysis (Summary):**

Albemarle (ALB) is experiencing a period of mixed signals. The stock has recently shown upward momentum, supported by rising lithium prices and positive news. However, historical performance has significantly lagged the S&P 500, and profitability is a concern, as reflected in negative EPS and fluctuating profit margins and ROE.

*   **Positive Factors:**
    *   Short-term upward price trend.
    *   Positive news related to lithium prices and demand.
    *   "Buy" analyst consensus.
    *   High expected return.
    *   Lithium is becoming an AI play.

*   **Negative Factors:**
    *   Significant underperformance compared to the S&P 500.
    *   High MDD and negative Alpha indicating high risk and underperformance relative to the market.
    *   Inconsistent profitability (negative EPS, fluctuating profit margins and ROE).
    *   Lower average analyst target price than current price.

**Overall Recommendation:**

Based on the data, Albemarle presents a high-risk, high-reward investment opportunity. The recent upward momentum and positive news surrounding lithium prices are encouraging. However, the company's historical underperformance, inconsistent profitability, and high volatility are significant concerns.  The MRI is medium and the hybrid signal is for 80% buying with caution.

**Disclaimer:** This analysis is based solely on the provided data and should not be considered financial advice. Investors should conduct their own research and consult with a financial professional before making any investment decisions.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.